Incretin (GLP‐1RA) injections are now generally the first injectable of choice in T2DM, having advantages over insulin in not needing feedback dose titration, being positive for weight trajectory, not themselves giving hypoglycaemia, and being widely (if expensively) available once weekly.31 Here, INS is linked to type 2 diabetes mellitus.